Xcout IntelImpact BioMedical, Inc.
Impact BioMedical Inc. is a pioneering biotechnology company incorporated in 2018 and based in Houston, Texas, dedicated to discovering, developing, and patenting innovative healthcare products, drug pipelines, and technology platforms.
Subscribe to see Impact BioMedical, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Impact BioMedical, Inc. at a glance
Impact BioMedical, Inc. is a biotech company headquartered in Houston, United States. It is publicly listed (IBO) with a market capitalisation of $37.9M. Xcout tracks 11 named people at Impact BioMedical, Inc., including Frank D. Heuszel (Chairman & Chief Executive Officer).
Impact BioMedical, Inc. leadership
- Frank D. HeuszelChairman & Chief Executive Officer
- Mark J. SuseckChief Operating Officer
- Todd D. MackoChief Financial Officer, Secretary & Treasurer
- Castel Berisford HibbertDirector
- Christian Thomas ZimmermanDirector
- David K KeeneDirector
5 more named people on record for Impact BioMedical, Inc., with roles, board committees and tenure — see the full roster →
Recent Impact BioMedical, Inc. news
- AcquisitionM&A communication (425)
- AcquisitionM&A communication (425)
Impact BioMedical, Inc. competitors
A few of Impact BioMedical, Inc.'s closest competitors — see the full list of competitors and alternatives →
EVOQ Medical, Inc. is a healthcare company engaged in drug pipelines, patents, clinical trials, and therapeutic technology platforms.
Indi Molecular, Inc. is a biotechnology company focused on drug pipelines, therapeutic areas, patents, and clinical trials.
ImStar Therapeutics Inc. is a biotechnology company headquartered in Vancouver, British Columbia, focused on breakthrough science and drug discovery.
Minerva Biotechnologies Corp. is a biotechnology holding company based in Woburn, Massachusetts, engaged in drug pipelines and patent development.
IpiNovyx Bio, Inc. is a biopharmaceutical company that discovers and develops targeted proteasome inhibitors to treat cancer, autoimmune, and inflammatory diseases. Utilizing a proprietary technology platform, the company focuses on advancing selective and reversible immunoproteasome inhibitors to create safer and more effective therapies for patients.
Irazú Bio partners with academic researchers and university centers to curate and advance translational research assets into IND-enabling studies and Phase 1 clinical trials. The company focuses on areas such as hypoxia tolerance, antiviral formulations, and adeno-associated virus gene therapy, subsequently licensing the developed assets to pharmaceutical companies or forming new ventures with venture capital groups.
Get Impact BioMedical, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Impact BioMedical, Inc. in Xcout Intel
- 11 named people with titles, LinkedIn and board committees
- 2 corporate events with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access